Evaluation of the Tolerance of Three Masks Under Dermatological Control.

Healthy Population Clinical Trial

Official title:

Monocentric, Open Study for the Evaluation of the Tolerance of Three Class I Medical Devices Under Dermatological Control.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05193799
• Other study ID #: 21E2022
• Status: Completed
• Phase: N/A
• Start date: January 3, 2022
• Est. completion date: February 17, 2022

Study information

• Verified date: March 2022
• Source: Groupe Kolmi Hopen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a monocentric, open and randomized study. The purpose is to evaluate the cutaneous tolerance of three medical masks (class I medical device) after 3 consecutive days of use on a population with normal or sensitive skin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 98
• Est. completion date: February 17, 2022
• Est. primary completion date: February 17, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Healthy Subject;

2. Sex: male or female ;

3. Age: more than 18 years ;

4. Phototype: I to IV on the Fitzpatrick scale;

5. For half of the population in each group : subject presenting a sensitive skin on the face confirmed by an interrogatory with the investigator (see Appendix 19.1).

6. Subjects who did not use any new cosmetic product on the face in the past 30 days and who agree not to change them during the study period.

7. Subject having given freely and expressly his/her informed consent;

8. For subjects randomized to group 3: Fit test FFP on M52014-WH

Exclusion Criteria:

In terms of population

1. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship;

2. Subject in a social or sanitary establishment;

3. Subject suspected to be non-compliant according to the investigator's judgment;

4. Subject enrolled in another clinical trial or which exclusion period is not over.

5. Subject majors under curatorship, safeguard of justice, activated future protection mandate or family authorization In terms of associated pathology

6. Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk;

7. Subject suffering from a severe or progressive disease.

8. Subject's with too many hairs, bears,(to put above) skin lesions, skin disease or severe acne on the face that could interfere with the tolerance evaluation.

9. Subject' who is allergic to one or several component of the studied devices. Relating to previous or ongoing treatment

10. Subject undergoing a topical treatment on the test area or a systemic treatment:

• anti-inflammatory medication and/or antihistamines during the 2 weeks prior to screening and during the study;

• corticosteroids during the 2 weeks and prior to screening and during the study;

• retinoids and/or immunosuppressors during the 3 months prior to screening and during the study;

11. Subject having started or changed any hormonal treatment during the three previous months.

In terms of lifestyle

12. Intensive exposure to sunlight or UV-rays within the previous month and/or foreseen during the study;

13. Subject planning to change her/his life habits during the study;

Related Conditions & MeSH terms

• Healthy Population

Intervention

Device:
• Investigational devices must be used 8 hours per day
During 3 consecutive days

Locations

Country	Name	City	State
France	Laboratoire Eurofins Dermscan Pharmascan	Villeurbanne

Sponsors (1)

Lead Sponsor	Collaborator
Groupe Kolmi Hopen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cutaneous tolerance	Evaluation of the percentage of subjects presenting no relevant clinical or functional signs of cutaneous intolerance after 3 days of use of the three medical devices	Days 3
Secondary	Subjective appreciation	Analysis of the subject's answer to a subjective evaluation questionnaire	3 days
Secondary	Number of Adverse event	Collection of cutaneous and systemic Adverse Event	3 days